Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 3
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 3

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderBioMarin Pharmaceutical · 57
Strongest available pathJohnson & Johnson · +64.6%
Widest latest marginJohnson & Johnson · 28.5%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1BMRN · Nasdaq

BioMarin Pharmaceutical

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2019Novato, California$12.63B market cap
View full Companies Radar profile
57Moderate
Snapshot price$65.23as of page date
Monthly-close return-15.6%five-year window
FY2025 revenue$3.22BBIOMARIN PHARMACEUTICAL INC
Net margin10.8%FY2025
P/E snapshot176.3xone ratio, not a verdict
Prism attention2.2%share across these five
Filing track recordRevenue, USD billions
+74.5%
$0$1.1B$2.1B$3.2BFY2021: $1.846BFY2022: $2.096BFY2023: $2.419BFY2024: $2.854BFY2025: $3.221B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 14.9%
52-week position74% through range
$49.26$70.98
News mentions3.4K
Community mentions29partial coverage
U.S.-scope patents5
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal54/100
Management stability90/100
Market position22/100
Capital-event signal87/100
Innovation pulse27/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 25 M&A involvements, 3 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 10 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2AGIO · Nasdaq

Agios Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008Cambridge, Massachusetts$2.01B market cap
View full Companies Radar profile
56Moderate
Snapshot price$33.68as of page date
Monthly-close return-27.0%five-year window
FY2025 revenue$0.05BAGIOS PHARMACEUTICALS, INC.
Net margin-764.0%FY2025
P/E snapshot-8.5xone ratio, not a verdict
Prism attention1.5%share across these five
Filing track recordRevenue, USD billions
-73.4%
$0$0.1B$0.1B$0.2BFY2020: $0.203BFY2022: $0.014BFY2023: $0.027BFY2024: $0.036BFY2025: $0.054B20202022202320242025
FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -28.2%
52-week position48% through range
$22.24$46.00
News mentions2.3K
Community mentions13partial coverage
U.S.-scope patents1399
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal76/100
Management stability90/100
Market position15/100
Capital-event signal70/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 2 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3MNKD · Nasdaq

MannKind Corp

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1991Los Angeles, California$1.29B market cap
View full Companies Radar profile
56Moderate
Snapshot price$4.01as of page date
Monthly-close return-7.8%five-year window
FY2025 revenue$0.35BMANNKIND CORP
Net margin1.7%FY2025
P/E snapshot31.5xone ratio, not a verdict
Prism attention0.6%share across these five
Filing track recordRevenue, USD billions
+362.6%
$0$0.1B$0.2B$0.3BFY2021: $0.075BFY2022: $0.100BFY2023: $0.199BFY2024: $0.286BFY2025: $0.349B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 46.7%
52-week position42% through range
$2.23$6.51
News mentions997
Community mentions24partial coverage
U.S.-scope patents1987
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal63/100
Management stability90/100
Market position19/100
Capital-event signal75/100
Innovation pulse22/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 7 asset-acquisition events and 20 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4NRIX · Nasdaq

Nurix Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2009San Francisco, California$2.68B market cap
View full Companies Radar profile
56Moderate
Snapshot price$25.78as of page date
Monthly-close return-14.0%five-year window
FY2025 revenue$0.08BNurix Therapeutics, Inc.
Net margin-314.9%FY2025
P/E snapshot-17.9xone ratio, not a verdict
Prism attention0.6%share across these five
Filing track recordRevenue, USD billions
+54.0%
$0$0.0B$0.1B$0.1BFY2024: $0.055BFY2025: $0.084B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 54.0%
52-week position88% through range
$8.20$28.23
News mentions910
Community mentions4partial coverage
U.S.-scope patents259
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal88/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5JNJ · NYSE

Johnson & Johnson

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1930Charleston, South Carolina$640.67B market cap
View full Companies Radar profile
55Moderate
Snapshot price$265.9as of page date
Monthly-close return+64.6%five-year window
FY2025 revenue$94.19BJOHNSON & JOHNSON
Net margin28.5%FY2025
P/E snapshot30.8xone ratio, not a verdict
Prism attention95.1%share across these five
Filing track recordRevenue, USD billions
+0.4%
$0$31.6B$63.3B$94.9BFY2021: $93.775BFY2022: $94.943BFY2023: $85.159BFY2024: $88.821BFY2025: $94.193B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.1%
52-week position90% through range
$173.3$276.5
News mentions146.7K
Community mentions1.0Kpartial coverage
U.S.-scope patents18790
Prism Insights

What sits behind the readiness signal

Observed risk 17/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position36/100
Capital-event signal76/100
Innovation pulse27/100
Management signal

No leadership-churn flag in the model; 8 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 197 M&A involvements, 49 asset-acquisition events and 55 contract events.

Innovation activity

Prism records 6 lifetime product-launch events, 0 in the latest 360 days, and 9 company announcements in that window.

Recent risk watch

Recent available records contain 7 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Johnson & Johnson
+64.6%
MannKind Corp
-7.8%
Nurix Therapeutics
-14.0%
BioMarin Pharmaceutical
-15.6%
Agios Pharmaceuticals
-27.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Johnson & Johnson
$94.19B
BioMarin Pharmaceutical
$3.22B
MannKind Corp
$0.35B
Nurix Therapeutics
$0.08B
Agios Pharmaceuticals
$0.05B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Johnson & Johnson
28.5%
BioMarin Pharmaceutical
10.8%
MannKind Corp
1.7%
Nurix Therapeutics
-314.9%
Agios Pharmaceuticals
-764.0%

Prism news attention

Normalized share across these five names; attention is not quality.

Johnson & Johnson
95.1%
BioMarin Pharmaceutical
2.2%
Agios Pharmaceuticals
1.5%
MannKind Corp
0.6%
Nurix Therapeutics
0.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Johnson & Johnson leads the conversation

It holds 95.1% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $94.19B.

Price path

Johnson & Johnson leads the available price paths

Its monthly-close return is +64.6% for the five-year window. At the other end, Agios Pharmaceuticals is -27.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Johnson & Johnson has the widest latest margin

Its FY2025 net margin is 28.5%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Nurix Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -17.9x while its five-year window price return is -14.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · BMRN

BioMarin Pharmaceutical

3,390available Prism news records

Prism top themes

Price action & investor response
156
Earnings & financial performance
59
Capital allocation & transactions
58
Leadership & governance
31
Macro demand & rates
25

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-33.1%504 latest 12m vs 753 prior 12m
2024-01: 17 mentions2024-02: 27 mentions2024-03: 22 mentions2024-04: 37 mentions2024-05: 30 mentions2024-06: 34 mentions2024-07: 18 mentions2024-08: 36 mentions2024-09: 38 mentions2024-10: 21 mentions2024-11: 17 mentions2024-12: 11 mentions2025-01: 22 mentions2025-02: 454 mentions2025-03: 35 mentions2025-04: 40 mentions2025-05: 38 mentions2025-06: 23 mentions2025-07: 15 mentions2025-08: 28 mentions2025-09: 25 mentions2025-10: 34 mentions2025-11: 22 mentions2025-12: 49 mentions2026-01: 39 mentions2026-02: 87 mentions2026-03: 43 mentions2026-04: 88 mentions2026-05: 71 mentions2026-06: 3 mentions2024-012026-06

Machine-classified coverage tone

91.2% positive+2.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 55stock price 44stock performance 37rare disease clinical trials 34rare disease treatment 33orphan drug pricing 30earnings report 24biosimilar market entry 21

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-06-10 · trend and themes shown through 2026-06
Areas of research · AGIO

Agios Pharmaceuticals

2,306available Prism news records

Prism top themes

Price action & investor response
76
Legal, arbitration & regulatory
45
Earnings & financial performance
26
Capital allocation & transactions
25
Leadership & governance
15

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-2.7%290 latest 12m vs 298 prior 12m
2024-02: 23 mentions2024-03: 12 mentions2024-04: 17 mentions2024-05: 50 mentions2024-06: 33 mentions2024-07: 19 mentions2024-08: 37 mentions2024-09: 21 mentions2024-10: 21 mentions2024-11: 10 mentions2024-12: 18 mentions2025-01: 21 mentions2025-02: 97 mentions2025-03: 15 mentions2025-04: 17 mentions2025-05: 19 mentions2025-06: 6 mentions2025-07: 16 mentions2025-08: 15 mentions2025-09: 25 mentions2025-10: 28 mentions2025-11: 35 mentions2025-12: 30 mentions2026-01: 23 mentions2026-02: 18 mentions2026-03: 21 mentions2026-04: 51 mentions2026-05: 31 mentions2026-06: 12 mentions2026-07: 1 mentions2024-022026-07

Machine-classified coverage tone

89.7% positive-1.4 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

rare disease clinical trials 35stock price 32rare disease treatment 17gene therapy rare diseases 17orphan drug pricing 16angiogenesis inhibitors 16stock performance 14share price 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-04-15–2026-07-15 · trend and themes shown through 2026-07
Areas of research · MNKD

MannKind Corp

997available Prism news records

Prism top themes

Price action & investor response
39
Capital allocation & transactions
20
Legal, arbitration & regulatory
13
Leadership & governance
12
Earnings & financial performance
11

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+68.1%153 latest 12m vs 91 prior 12m
2024-01: 5 mentions2024-02: 8 mentions2024-03: 15 mentions2024-04: 12 mentions2024-05: 14 mentions2024-06: 16 mentions2024-07: 7 mentions2024-08: 9 mentions2024-09: 7 mentions2024-10: 3 mentions2024-11: 14 mentions2024-12: 17 mentions2025-01: 0 mentions2025-02: 19 mentions2025-03: 3 mentions2025-04: 1 mentions2025-05: 6 mentions2025-06: 5 mentions2025-07: 6 mentions2025-08: 21 mentions2025-09: 9 mentions2025-10: 11 mentions2025-11: 18 mentions2025-12: 14 mentions2026-01: 12 mentions2026-02: 14 mentions2026-03: 15 mentions2026-04: 9 mentions2026-05: 23 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

87.8% positive-3.8 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

type 1 diabetes insulin regimen 17insulin injection techniques 16insulin administration 16inhaled insulin 15insulin pump delivery 15insulin-dependent diabetes control 14insulin syringes 13subcutaneous insulin 13

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-02 · trend and themes shown through 2026-06
Areas of research · NRIX

Nurix Therapeutics

910available Prism news records

Prism top themes

Price action & investor response
60
Capital allocation & transactions
30
Earnings & financial performance
25
Legal, arbitration & regulatory
15
Leadership & governance
6

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-3.0%226 latest 12m vs 233 prior 12m
2024-01: 7 mentions2024-02: 15 mentions2024-03: 15 mentions2024-04: 38 mentions2024-05: 20 mentions2024-06: 23 mentions2024-07: 16 mentions2024-08: 7 mentions2024-09: 12 mentions2024-10: 28 mentions2024-11: 14 mentions2024-12: 14 mentions2025-01: 27 mentions2025-02: 22 mentions2025-03: 28 mentions2025-04: 29 mentions2025-05: 20 mentions2025-06: 16 mentions2025-07: 25 mentions2025-08: 6 mentions2025-09: 5 mentions2025-10: 28 mentions2025-11: 19 mentions2025-12: 26 mentions2026-01: 27 mentions2026-02: 13 mentions2026-03: 6 mentions2026-04: 49 mentions2026-05: 16 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

92.6% positive-6.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

checkpoint inhibitors lymphoma 24antibody-drug conjugates lymphoma 21lymphoplasmacytic lymphoma 17stock performance 16t-cell lymphoma 13angiogenesis inhibitors 13cell-based therapies 13cancer biomarkers 12

Keyword tag occurrences in available Prism news records.

Coverage: 2013-05-01–2026-06-13 · trend and themes shown through 2026-06
Areas of research · JNJ

Johnson & Johnson

146,691available Prism news records

Prism top themes

Price action & investor response
2,563
Macro demand & rates
1,865
Capital allocation & transactions
876
Leadership & governance
823
Earnings & financial performance
639

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-33.9%9,484 latest 12m vs 14,347 prior 12m
2024-03: 796 mentions2024-04: 797 mentions2024-05: 971 mentions2024-06: 700 mentions2024-07: 728 mentions2024-08: 758 mentions2024-09: 682 mentions2024-10: 689 mentions2024-11: 695 mentions2024-12: 539 mentions2025-01: 1,040 mentions2025-02: 3,975 mentions2025-03: 801 mentions2025-04: 1,116 mentions2025-05: 875 mentions2025-06: 529 mentions2025-07: 1,032 mentions2025-08: 2,374 mentions2025-09: 1,112 mentions2025-10: 1,046 mentions2025-11: 809 mentions2025-12: 818 mentions2026-01: 1,097 mentions2026-02: 1,223 mentions2026-03: 799 mentions2026-04: 1,555 mentions2026-05: 798 mentions2026-06: 224 mentions2026-07: 2 mentions2026-08: 1 mentions2024-032026-08

Machine-classified coverage tone

80.3% positive+6.8 pp vs preceding four quarters
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine candidates 1,046vaccine trials 906vaccination campaigns 884mass vaccination sites 745vaccine immunogenicity 720covid-19 vaccine development 612pandemic vaccine stockpiling 597pandemic vaccine deployment 586

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-03 · trend and themes shown through 2026-08
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

BMRN

BioMarin Pharmaceutical

29 mentions
Stock and valuation
7

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 29 records remained after filtering.

JNJ

Johnson & Johnson

1,013 mentions
Stock and valuation
255
Products, pricing and logistics
251
Workplace and hiring
125
Other company context
12

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,013 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

BMRN

BioMarin Pharmaceutical

through 2026-05-04
Earnings releases 39Company announcements 34M&A 16Leadership changes 11Listing / IPO 8
  1. M&A

    President and CEO Alexander Hardy said the Amicus deal closed last week and described it as “a new and exciting chapter” that increases portfolio diversification.

  2. Earnings releases

    First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion , Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint,

  3. Company announcements

    BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m. ET to discuss fourth quarter and full-year 2025 financial results and provide a general business update.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AGIO

Agios Pharmaceuticals

through 2026-04-29
Earnings releases 13Company announcements 3Leadership changes 2Listing / IPO 2M&A 2
  1. Earnings releases

    Mitapivat (PYRUKYND ® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025

  2. M&A

    Three years later, Servier acquired the clinical-stage oncology assets of Agios Pharmaceuticals for $1.8 billion up front.

  3. Listing / IPO

    a $475 million follow-on for Agios Pharmaceuticals Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MNKD

MannKind Corp

through 2026-01-08
Earnings releases 29Business contracts 8Leadership changes 8Company announcements 6Listing / IPO 4
  1. Company announcements

    MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals

  2. Earnings releases

    MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 million in net revenue,

  3. M&A

    MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NRIX

Nurix Therapeutics

through 2026-04-07
Earnings releases 11Company announcements 7Listing / IPO 4Regulatory 2Leadership changes 1
  1. Earnings releases

    Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is projected to issue its Q1 2026 results before the market opens on Tuesday, April 14th.

  2. Leadership changes

    On November 6, 2025, Nurix Therapeutics appointed Roger Dansey, M.D., to its board of directors and as a member of the Clinical and Commercialization Committee.

  3. Company announcements

    Nurix Therapeutics, Inc. (Nasdaq: NRIX), ... today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

JNJ

Johnson & Johnson

through 2026-04-30
Lawsuits 177Earnings releases 96M&A 59Leadership changes 39Company announcements 30
  1. Leadership changes

    Johnson & Johnson (NYSE: JNJ ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026.

  2. Earnings releases

    The company reported Q1 sales growth of 9.9 percent year-over-year to $24.1 billion, with operational growth of 6.4 percent and adjusted operational growth of 5.3 percent.

  3. Lawsuits

    Fortis Advisors, representing Auris Health’s former stockholders, sued J&J, claiming it failed to honor its contractual obligations.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 11–18. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Johnson & Johnson and Johnson & Johnson

Johnson & Johnson has the largest displayed latest revenue at $94.19B; Johnson & Johnson has the widest displayed latest margin at 28.5%.

Open Johnson & Johnson in Companies Radar
Comparisons
Anomalies

Johnson & Johnson has the widest attention-readiness rank gap

It ranks #1 by measured news attention (95.1%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Johnson & Johnson in Companies Radar

MannKind Corp shows a price-operating divergence to inspect

Its displayed filing-revenue change is +362.6% while its available monthly-close return is -7.8%. The signs differ, but the two measures cover different windows and do not establish causality.

Open MannKind Corp in Companies Radar
Explanations

Attention measures coverage volume, not quality

Johnson & Johnson's 95.1% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Johnson & Johnson in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open BioMarin Pharmaceutical's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 57/100 score.

Open BioMarin Pharmaceutical in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon